What are the maintenance doses of tirzepatide (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist) for a patient who has reached their goal weight?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maintenance Dosing of Tirzepatide After Reaching Goal Weight

Continue tirzepatide at the maximum tolerated dose (5 mg, 10 mg, or 15 mg weekly) indefinitely, as long-term use is necessary to maintain weight loss benefits and cessation leads to significant weight regain. 1, 2

Recommended Maintenance Approach

There is no dose reduction after achieving goal weight. The evidence consistently demonstrates that:

  • Patients must remain on their effective dose long-term to sustain weight loss, as discontinuation results in substantial weight regain (11.6% of lost weight regained after 52 weeks with similar GLP-1 medications) 2
  • The medication must be used in conjunction with lifestyle modifications for optimal maintenance of results 1, 2
  • Tirzepatide requires lifelong use for sustained weight management benefits 1

Specific Maintenance Dosing

The maintenance dose is determined by the maximum tolerated dose achieved during titration:

  • 5 mg weekly: Produces 15.0% weight loss at 72 weeks 1
  • 10 mg weekly: Produces 19.5% weight loss at 72 weeks 1
  • 15 mg weekly: Produces 20.9% weight loss (maximum efficacy) at 72 weeks 1, 3

Continue the dose that achieved the patient's goal weight without reduction. 1

Monitoring During Maintenance Phase

  • Assess effectiveness and safety at least quarterly after the initial 3-month period 1
  • Monitor blood pressure as weight maintenance may require adjustment of antihypertensive medications 1
  • Watch for delayed absorption of oral medications with narrow therapeutic indices 1
  • Assess for gallbladder symptoms and pancreatitis signs as ongoing risks 1, 2

Critical Clinical Pearls

Weight regain is expected if tirzepatide is discontinued, making indefinite continuation at the effective dose the standard approach rather than dose reduction or cessation. 2 This differs fundamentally from short-term weight loss interventions and requires counseling patients about lifelong treatment expectations at the outset. 1, 2

The gastrointestinal side effects that predominate during dose escalation (nausea 12-24%, diarrhea 15-17%, vomiting 6-10%) typically decrease over time during maintenance therapy. 4, 5

Cost considerations remain significant at approximately $1,272 per 30-day supply, and insurance coverage variability may influence long-term adherence to maintenance therapy. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.